Replies to post #235034 on Biotech Values

[DewDiligence]

VYGR—(-8%/PM)—HD program runs into glitch:

https://finance.yahoo.com/news/voyager-therapeutics-announces-third-quarter-210000462.html

For our Huntington’s disease program, the FDA has provided clarity regarding the additional information it is requesting pursuant to our IND filing. We plan to work with the FDA to respond to these requests to allow for an IND clearance and the start of VY-HTT01’s clinical evaluation,” said Andre Turenne, President and CEO of Voyager.

So, both the PD and HD programs are now on FDA clinical hold.